

Table 1. Eligibility Criteria and Exclusion Criteria for Intravenous Thrombolysis²⁰

| Eligibility Criteria | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 0-3 Hours <ul style="list-style-type: none"> • Age \geq 18 years • Acute-onset stroke symptoms (severe, moderate, or mild, but disabling) | 3-4.5 Hours* <ul style="list-style-type: none"> • Age \leq 80 years • No history of both diabetes mellitus and prior stroke • NIHSS score \leq 25 • Not taking any oral anticoagulation agents |
| Exclusion Criteria | |
| <ul style="list-style-type: none"> • Intracranial hemorrhage on CT or MRI • CT evidence of obvious hypodensity • Ischemic stroke within prior 3 months • Severe head trauma within prior 3 months • Intracranial or spinal surgery within prior 3 months • History of intracranial hemorrhage • Symptoms suggestive of subarachnoid hemorrhage • Gastrointestinal bleeding event within 21 days of the stroke event • Platelets $<$ 100,000/mm³; INR $>$ 1.7; aPTT $>$ 40 sec; PT $>$ 15 sec • Treatment dose of LMWH within the last 24 hours • Warfarin use with INR $>$ 1.7 • NOAC [DOAC] use, unless normal laboratory result (thrombin time for dabigatran; direct factor Xa activity assays for apixaban, rivaroxaban, and edoxaban) or if not taken $>$ 48 hours (if normal renal function) • Clinical suspicion of infective endocarditis • Known or suspected aortic arch dissection • Intra-axial intracranial neoplasm • Giant unruptured or unsecured aneurysm • High burden of cerebral microbleeds ($>$ 10) demonstrated on MRI (if MRI available) | |
| Relative Exclusion Criteria (Individualized decisions should be made) | |
| <ul style="list-style-type: none"> • Pre-existing disability or dementia; individual considerations should be taken, as thrombolytic therapy for acute therapy may be reasonable in this population • Seizures at onset, unless stroke is proven • Lumbar puncture within previous 7 days • Arterial puncture in a noncompressible vessel within previous 7 days • Major trauma not involving the head within previous 14 days • Major surgery within previous 14 days (discuss bleeding risk with surgeon) • Active menstruation with history of menorrhagia • Intracranial arterial dissection (unknown risk, not well established) • Intracranial aneurysm, unruptured or unsecured, small to moderate size ($<$ 10 mm) • Intracranial vascular malformations • Extra-axial intracranial neoplasm • Systemic malignancy with $<$ 6 months' life expectancy | |

*Time window not currently approved by the United States Food and Drug Administration. Abbreviations: aPTT, activated partial thromboplastin time; CT, computed tomography; DOAC, direct oral anticoagulant; INR, international normalized ratio; LMWH, low-molecular-weight heparin; MRI, magnetic resonance imaging; NIHSS, National Institutes of Health Stroke Scale; NOAC, novel oral anticoagulant; PT, prothrombin time; PTT, partial thromboplastin time.